- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/22 - Anxiolytics
Patent holdings for IPC class A61P 25/22
Total number of patents in this class: 2318
10-year publication summary
59
|
60
|
78
|
140
|
198
|
169
|
200
|
238
|
200
|
66
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
AstraZeneca AB | 3042 |
54 |
Takeda Pharmaceutical Company Limited | 2961 |
52 |
Taisho Pharmaceutical Co., Ltd. | 844 |
47 |
F. Hoffmann-La Roche AG | 7958 |
38 |
Hoffmann-La Roche Inc. | 3060 |
29 |
H. Lundbeck A/S | 1252 |
29 |
Banyu Pharmaceutical Co., Ltd. | 107 |
22 |
Janssen Pharmaceutica N.V. | 3839 |
21 |
Société des Produits Nestlé S.A. | 9672 |
20 |
Intra-Cellular Therapies, Inc. | 378 |
19 |
Sumitomo Pharma Co., Ltd. | 626 |
19 |
Daiichi Sankyo Company, Limited | 1829 |
17 |
Nippon Chemiphar Co., Ltd. | 233 |
17 |
Sage Therapeutics, Inc. | 312 |
17 |
Sumitomo Dainippon Pharma Co., Ltd. | 226 |
17 |
Les Laboratoires Servier | 599 |
16 |
Glaxo Group Limited | 4496 |
15 |
The Trustees of Columbia University in the City of New York | 3440 |
14 |
Bionomics Limited | 90 |
14 |
Eisai R&D Management Co., Ltd. | 1304 |
14 |
Other owners | 1827 |